SCHEDULE 13G/A: Janus Henderson Group Discloses 5.4% Stake in Tenax Therapeutics
Beneficial Ownership Report (Schedule 13G Amendment)
Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.4% beneficial ownership stake in Tenax Therapeutics, Inc. as of December 31, 2024.
Summary
- Janus Henderson Group PLC, a global asset manager, has filed an Amendment No. 2 to its Schedule 13G regarding its beneficial ownership in Tenax Therapeutics, Inc.
- As of December 31, 2024, Janus Henderson Group PLC beneficially owned 193,182 shares of Tenax Therapeutics' Common Stock.
- This ownership represents 5.4% of the total outstanding shares of Tenax Therapeutics.
- Janus Henderson Group PLC holds shared voting power and shared dispositive power over all 193,182 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Tenax Therapeutics.
- Janus Henderson Group PLC is classified as an Investment Adviser (IA) and a Parent Holding Company (HC) for the purpose of this filing.
- Indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML are registered investment advisers furnishing investment advice to Managed Portfolios, through which these shares are held.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory filing.
Positives
- The disclosure of a 5.4% stake by a reputable institutional investor like Janus Henderson Group PLC may signal confidence in Tenax Therapeutics to other investors.
- The filing confirms that the shares are held in the ordinary course of business, indicating a long-term investment perspective rather than an activist intent.
Negatives
- NA
Risks
- NA
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Tenax Therapeutics' future performance or Janus Henderson Group's future investment intentions beyond the ordinary course of business.
Industry Context
Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's voting class of securities, but do not intend to influence or control the issuer. This filing indicates that a significant institutional investor, Janus Henderson Group, maintains a substantial passive stake in Tenax Therapeutics, which is common practice for asset management firms holding diversified portfolios.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially provide a degree of stability or confidence in the stock.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of execution of Power of Attorney for SEC filings by Janus Henderson Group plc. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting date for beneficial ownership). |
| 2025-02-14 | Date of filing of the Schedule 13G Amendment No. 2. |
Keywords
Tenax Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, Healthcare, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.